Welcome to the News You Might Have Missed, a weekly roundup of news items to help you catch up and stay informed.
It was a busy week with lots of news, have a look and see you next week for another update.
Lead DMT-assisted therapy candidate SPL026’s clinical development program strengthened with the addition of two clinical trials planned for 2022. SPL028, a deuterated DMT candidate with Composition of Matter patent protection in the UK, moves towards Phase I clinical trial in H2 2022 on positive preclinical data.
Dr. Paul Thielking, Chief Scientific Officer at Novamind: “The Psilocybin Trial is a key step in moving psilocybin through the clinical development process and closer to regulatory approval. Today marks another exciting milestone for our team as we continue to support drug developers, not-for-profits and academic partners to accelerate psychedelic research and improve patient outcomes.”
NeonMind Reports Business Highlights on Partnership Activities, Clinical Pipeline and Corporate Developments
– Completed concrete milestones in its strategy to become a leading psychedelic drug developer and specialty clinics operator.
– Developed clear drug development pathway for NEO-001, the industry’s first psilocybin-based obesity treatment with near-term clinical milestones.
– Partnered with well-established specialty treatment providers, SRx Health Solutions and BioScript Solutions to build out a network of NeonMind-branded specialty mental health clinics across Canada.
Blackhawk’s MindBio Therapeutics Invests NZ$2.3 Million to Fast Track Psychedelic Microdosing Phase 2 Clinical Trials
MindBio is investing in world-class facilities to fast track its microdosing clinical trials. MindBio’s Phase 1 clinical trial microdosing LSD (Lysergic Acid Diethylamide) to 80 patients at home is due for completion shortly. Two continuation studies will follow from the NZ$2,300,000 investment including a Phase 2 clinical trial microdosing LSD in patients with major depressive disorder and a Phase 2 clinical trial microdosing LSD in late-stage cancer patients starting this year.
Numinus has just received approval from Health Canada to study Ayahuasca and San Pedro. This expansion of their research license shows that the feds acknowledge the potential of plant medicine, and will support at least its research for now.
“In the second half of 2021, we continued to accomplish several significant milestones and continued to execute in the face of one of the most difficult environments for publicly-traded biotech companies that I’ve seen in my career,” said Raj Mehra Ph.D., Chairman and CEO of Seelos.